NCT04161391 2024-06-13Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTurning Point Therapeutics, Inc.Phase 1/2 Terminated41 enrolled 18 charts
NCT02709889 2020-10-19Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsAbbViePhase 1/2 Terminated200 enrolled 21 charts